Psyence BioMed expands U.S. ibogaine research with Texas unit

Psyence BioMed's U.S. Expansion

Psyence Biomedical Ltd., a biopharmaceutical firm listed on Nasdaq, is strengthening its presence in the United States by establishing a new subsidiary in Texas. This move is part of the company's strategy to advance the development of ibogaine, a nature-derived neuroplastogen, for mental health and substance-use disorders. The subsidiary, named Texas Ibogaine Research Corporation (TIRC), was announced on September 14, 2026, and aims to streamline the supply and regulatory processes for pharmaceutical-grade ibogaine in the U.S.

Centralizing Ibogaine Development

According to the announcement, TIRC will focus on consolidating the supply, manufacturing, and regulatory documentation of ibogaine. This strategic move is intended to facilitate more efficient interactions with U.S. federal agencies, state programs, and research partners. TIRC is expected to hold U.S. rights to ibogaine produced by PsyLabs, subject to licensing agreements, and will serve as the primary entity in regulatory and clinical discussions within the country.

Leadership and Strategic Goals

The leadership team for TIRC will include key figures from Psyence BioMed, with CEO Jody Aufrichtig also taking on the role of TIRC's chief executive. Dr. John Thorne will lead the project, supported by CFO Warwick Corden-Lloyd and in-house legal resources. This initiative reflects Psyence BioMed's commitment to creating a comprehensive platform for ibogaine development in the U.S., although it will require navigating complex licensing and regulatory landscapes.

Why It Matters

The establishment of TIRC comes amid growing U.S. policy support for neuroplastogens, highlighted by an executive order on April 18, 2026, aimed at accelerating research in this field. Psyence BioMed's move to align with these emerging frameworks positions the company to potentially play a significant role in the evolving landscape of ibogaine research and development.

Psyence BioMed's efforts to expand its ibogaine research capabilities in the U.S. underscore the increasing interest in neuroplastogens as potential treatments for mental health and substance-use disorders.